Datapoint: FDA Approves Avastin Biosimilar

The FDA last week approved Celltrion Healthcare’s Avastin biosimilar across six of the oncology powerhouse’s indications, including metastatic colorectal cancer and recurrent or metastatic non-squamous non-small cell lung cancer. The angiogenesis inhibitor, known as Vegzelma, is the sixth biosimilar to receive FDA approval this year. For the treatment of colorectal cancer, Avastin currently holds covered or better status for 51% of all insured lives under the pharmacy benefit, and 86% of insured lives under the medical benefit.

SOURCE: MMIT Analytics, as of 10/3/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 2

Datapoint: Blue Shield of California Launches Virtual-First Plan

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 1

Datapoint: FDA Approves Lilly’s Jaypirca in Blood Cancer

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 31

Datapoint: Independence Blue Cross to Launch Advanced Network for Gene Therapies

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today